Innovative Approaches to Diagnosing and Treating Heart Valve Disorders: The Importance of Minimally Invasive Techniques and Bioengineered Valves

Abstract

This review article delves into the evolving landscape of heart valve disorder diagnosis and treatment, highlighting groundbreaking advancements in minimally invasive surgical techniques and bioengineered heart valves. These cutting-edge innovations present transformative alternatives for patients who are at higher risk for conventional open-heart surgery, delivering key benefits such as minimized surgical trauma, accelerated recovery periods, and superior clinical outcomes. Bioengineered heart valves, designed to emulate the functionality of native tissue, address the longstanding limitations associated with mechanical and bioprosthetic valves by significantly enhancing both durability and performance. A collaborative approach, incorporating advanced diagnostic tools like echocardiography alongside interdisciplinary expertise, fuels these innovations. This integrated synergy facilitates the development of personalized treatment protocols tailored to each patient’s unique needs, driving notable improvements in the management of heart valve disorders. Such progress not only marks a pivotal shift in cardiovascular care but also sets the foundation for the future of precision medicine, offering the promise of ongoing enhancements in patient outcomes and treatment efficacy.

Keywords: Heart valve disorders, Minimally invasive surgery, Bioengineered heart valves, Open-heart surgery alternatives, Personalized treatment strategies, Echocardiography, Mechanical valves, Bioprosthetic valves, Cardiovascular innovations, Precision medicine

Introduction

Heart valve disorders are a key area of focus within cardiovascular medicine, presenting complex challenges for both patients and healthcare providers. These disorders, which include stenosis, regurgitation, and prolapse, require highly specialized diagnostic and therapeutic strategies to address the unique needs of each condition. The evolution of accurate diagnostic methods and innovative treatment options has been instrumental in enhancing patient outcomes and improving quality of life for those affected [1-3].

Recent years have witnessed a transformative shift in the management of heart valve disorders, driven by advancements in minimally invasive surgical techniques and the development of bioengineered heart valves. These cutting-edge innovations have opened new avenues for personalized care, enabling clinicians to deliver more precise diagnoses and craft treatment plans tailored to individual patient profiles [4]. Historically, surgical repair or replacement has served as the cornerstone for managing severe or symptomatic valve dysfunction. However, the introduction of minimally invasive approaches has broadened the spectrum of treatment options, offering safer alternatives for patients deemed high-risk for conventional open-heart surgery [5,6].

In parallel, the field of bioengineering has introduced significant advancements in valve replacement therapy. Bioengineered heart valves, designed to replicate the structural and functional characteristics of native valves, aim to address the limitations traditionally associated with mechanical and bioprosthetic valves. These innovations not only enhance clinical outcomes but also spur further research and development in cardiovascular medicine, pushing the boundaries of what is possible [7,8].

As diagnostic technologies and treatment methodologies continue to evolve, clinicians are better positioned to provide optimal care for patients with heart valve disorders. Staying at the forefront of emerging technologies and fostering interdisciplinary collaboration is essential to improving patient outcomes and advancing toward more personalized and effective management strategies [1,9].

This article provides an in-depth examination of the current state of heart valve disorder diagnosis and treatment, with a particular emphasis on the remarkable progress made in minimally invasive surgery and bioengineered valve development [10]. These breakthroughs have not only revolutionized patient care but also catalyzed ongoing research in this rapidly advancing field. Heart valve disorders, including valvular heart disease, continue to pose significant challenges, but the introduction of precise diagnostic tools and innovative treatments has transformed their management. We delve into the specific advantages of minimally invasive surgical techniques, such as reduced trauma, quicker recovery, and improved long-term outcomes. Additionally, we explore the profound impact of bioengineering, which has opened up exciting opportunities to develop artificial valves that closely emulate native valve functionality [11,12].

These advancements promise to revolutionize heart valve re placement procedures, greatly improving patient prognosis. However, they also raise important considerations regarding material selection and fabrication techniques for bioengineered heart valves [13,14]. By examining these developments, we offer valuable insights into the challenges, innovations, and future directions in the field, ultimately contributing to enhanced patient care and outcomes in this critical domain of cardiovascular medicine.

Heart Valve Disorders

Heart valve disorders encompass a diverse array of conditions, including stenosis, regurgitation, and prolapse, each presenting unique challenges for diagnosis and management [15]. Stenosis, characterized by the narrowing of a heart valve, places an increased workload on the heart, often manifesting in symptoms such as chest pain and shortness of breath. Aortic stenosis, frequently associated with aging and calcification, along with mitral stenosis, often resulting from rheumatic fever, are prevalent forms that underscore the critical need for early detection and timely intervention [16,17]. Regurgitation occurs when a valve fails to close properly, leading to backflow of blood and heart failure symptoms. Notably, transcatheter interventions, such as percutaneous mitral valve repair, have demonstrated significant promise in alleviating symptoms and enhancing the quality of life for patients suffering from regurgitation [18]. Furthermore, Baumgartner, et al., (2017) provide updated guidelines on managing aortic stenosis, emphasizing the importance of understanding its pathophysiology, clinical presentation, and treatment options. Mitral regurgitation, often characterized by the backflow of blood into the left atrium during systole due to mitral valve dysfunction, is evaluated by Nishimura, et al., (2020), who compare surgical and transcatheter mitral valve repair outcomes [19,20]. Tricuspid regurgitation, caused by retrograde blood flow from the right ventricle into the right atrium, is explored by Topilsky, et al., (2014) in the context of left-sided heart valve surgery [21]. Aortic regurgitation, where blood leaks back into the left ventricle from the aorta during diastole, is investigated by Otto, et al., (2018), focusing on diagnostic modalities and risk stratification [15]. Mitral stenosis, marked by the narrowing of the mitral valve orifice, is systematically reviewed by Iung, et al., (2016), outlining various management strategies. Lastly, infective endocarditis, an infection that commonly affects heart valves, is studied by Murdoch, et al., (2009), highlighting the critical importance of early diagnosis and appropriate antibiotic therapy. These comprehensive insights are essential for optimizing patient care and outcomes in the realm of heart valve disorders [22,23].

Diagnostic Methods

Accurate diagnostic tools are paramount in assessing heart valve disorders, facilitating precise diagnosis and effective treatment planning. Echocardiography, encompassing Transthoracic Echocardiography (TTE) and Transesophageal Echocardiography (TEE), provides real-time visualization of valve structure and function [24]. Similarly, cardiac Magnetic Resonance Imaging (MRI) of fers detailed insights into valve morphology and function, featuring superior soft tissue contrast and multiplanar imaging capabilities [25]. Cardiac CT is particularly valuable in scenarios where echocardiography yields inconclusive results, providing accurate assessments of valve morphology and coronary artery anatomy [26]. Cardiac catheterization enables direct pressure measurements and valve gradient assessments, playing a vital role in hemodynamic evaluation and guiding therapeutic interventions [27]. Additionally, biomarkers such as Brain Natriuretic Peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) assist in diagnosis, risk stratification, and monitoring disease progression [28]. Emerging technologies, including 3D printing and modeling, facilitate the creation of patient-specific anatomical models, enhancing preoperative planning and simulation of valve interventions [29]. Collectively, these diagnostic modalities enrich our understanding of heart valve disorders, thereby improving patient care and outcomes.

Treatment Modalities

The evolution of treatment strategies for heart valve disorders has significantly enhanced patient care and outcomes [30]. Recent advancements in bioengineering have led to the development of bioengineered heart valves designed to address the limitations of traditional mechanical and bioprosthetic valves. These bioengineered valves provide improved durability, biocompatibility, and hemodynamic performance, offering patients a more functional and lasting solution.

In addition, the advent of minimally invasive surgical techniques has expanded treatment options, minimizing the risks associated with conventional open-heart surgeries. The development of percutaneous closure devices has facilitated less invasive procedures, resulting in shorter recovery times and decreased complications [30]. Such innovations not only broaden the pool of patients eligible for heart valve procedures but also enhance outcomes by minimizing complications and promoting quicker recoveries.

Traditional Treatment Approaches

Traditional management of heart valve disorders encompasses various strategies aimed at symptom alleviation, optimizing cardiac function, and preventing complications. Medical management, as articulated in the ACC/AHA guidelines by Nishimura, et al., (2020), employs pharmacotherapy, including diuretics, vasodilators, anticoagulants, and antiarrhythmics, to manage symptoms and mitigate risks associated with heart failure and thromboembolism [20]. Surgical interventions provide definitive treatment options, including valve repair or replacement procedures. A study by Leon, et al., (2016) highlights the efficacy of Transcatheter Aortic Valve Replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis [30].

Balloon valvuloplasty, as explored by Arora, et al., (2019), offers a minimally invasive approach for treating valve stenosis by dilating narrowed valves using a balloon catheter, particularly beneficial in cases of mitral and pulmonary valve stenosis [31]. Anticoagulation therapy, indicated for mechanical heart valve replacements or atrial fibrillation, aims to prevent thromboembolic events, with direct oral anticoagulants (DOACs) demonstrating comparable efficacy and improved safety profiles relative to warfarin [32]. Valve repair techniques, including annuloplasty and chordal-sparing procedures, are preferred for degenerative mitral regurgitation, yielding favorable long-term outcomes and survival benefits compared to valve replacement [33]. Together, these traditional treatment modalities contribute to a comprehensive strategy for managing heart valve disorders, addressing both symptom relief and disease progression.

Less Invasive Surgical Options

Less invasive surgical options have emerged as promising alternatives for managing heart valve disorders, offering benefits such as reduced trauma, shorter recovery times, and improved patient outcomes. Minimally Invasive Valve Surgery (MIVS) employs small incisions, enabling direct visualization for valve repair or replacement while minimizing tissue damage [34]. Robotic-Assisted Valve Surgery enhances precision through robotic arms controlled by surgeons, with evidence showing favorable perioperative outcomes compared to conventional approaches [35]. Transcatheter Valve Interventions, including TAVR and Transcatheter Mitral Valve Repair (TMVR), utilize catheterization techniques, demonstrating non-inferiority to surgical methods in terms of mortality and stroke rates [36]. Percutaneous Balloon Valvuloplasty effectively treats valve stenosis, yielding significant improvements in valve area and symptom relief [37]. Furthermore, sutureless and rapid deployment valve prostheses facilitate easier implantation and reduced operative times, enhancing the appeal of minimally invasive surgery [38]. These advancements collectively contribute to superior patient care and an expanded array of treatment options for heart valve disorders.

Collaborative Innovation in Heart Valve Disorder Management

Recent years have witnessed remarkable advancements in the diagnosis and treatment of heart valve disorders, ushering in transformative innovations that are reshaping cardiovascular medicine [39]. These breakthroughs span a spectrum of developments, from refining minimally invasive surgical techniques to the creation of bioengineered heart valves, all aimed at enhancing patient care and outcomes. Significantly, advancements in transcatheter interventions have propelled the field forward, particularly with technologies such as TAVR and TMVR. The PARTNER 3 trial, conducted by Mack, et al., (2019), underscored the safety and efficacy of TAVR in low-risk patients, expanding its indications and influencing clinical practice guidelines [36]. Similarly, innovations in TMVR, exemplified by the MitraClip system, have resulted in notable reductions in heart failure hospitalizations and mortality, as evidenced in the COAPT trial [40].

Robotic-assisted valve surgery has also made impressive strides, with studies such as that by Murphy, et al., (2021) demon strating excellent procedural success rates and favorable short-term outcomes in mitral valve repair [36]. Enhanced imaging technologies and navigation systems further augment surgical precision, as illustrated in research by Malvindi, et al., (2020), which explores augmented reality-assisted procedures for minimally invasive mitral valve repair. The introduction of newer percutaneous edgeto- edge repair devices, such as the Pascal system, shows promise for improving procedural success rates and the durability of mitral valve repair, as reported in the CLASP IID/IIF trial by Nickenig, et al., (2021) [41,42]. Collectively, these advancements signify a paradigm shift in managing heart valve disorders, offering patients more accurate diagnostic methods, effective treatment options, and improved long-term outcomes. Collaboration among clinicians, researchers, engineers, and other stakeholders is crucial in driving innovation within the field. By harnessing interdisciplinary expertise, fostering technological advancements, and translating research findings into clinical practice, collaborative approaches enhance patient care and outcomes in heart valve disorder management [39-43].

Minimally Invasive Surgical Techniques

The emergence of minimally invasive surgical techniques has revolutionized the management of heart valve disorders [34]. These advanced methods, employing small incisions and specialized instruments, significantly reduce trauma and accelerate recovery times while enhancing patient outcomes compared to traditional open-heart surgery. Moreover, minimally invasive approaches lower the risk of infection and shorten hospital stays, making them highly appealing for many patients. Collaboration among clinicians, researchers, engineers, and other stakeholders is vital for driving innovation, sharing knowledge, and developing comprehensive solutions for patients with heart valve disorders. This multidisciplinary approach combines expertise from various fields to address the complex challenges associated with these conditions. The evolution of accurate diagnostic methods, utilizing sophisticated imaging techniques such as echocardiography, cardiac MRI, and CT scans, has improved early detection and evaluation of heart valve disorders. These advancements facilitate timely and effective treatment planning, enabling healthcare providers to tailor interventions to individual patient needs.

Furthermore, the integration of telemedicine into the management of heart valve disorders has enhanced patient access to specialized care. Virtual consultations, remote monitoring, and tele-rehabilitation programs improve patient engagement and adherence to treatment plans. This digital transformation empowers patients to actively participate in their care, fostering better communication and follow-up with healthcare providers. The management of heart valve disorders has advanced significantly in recent years, driven by collaborative efforts, technological innovations, and the integration of multidisciplinary approaches. The combination of minimally invasive surgical techniques, improved diagnostic methods, and advancements in patient-centered care has enhanced treatment outcomes and transformed the landscape of cardiovascular medicine. Moving forward, continued collaboration among healthcare professionals, researchers, and engineers will be essential to further optimize management strategies and improve patient outcomes in the realm of heart valve disorders.

Development of Bioengineered Heart Valves

The emergence of bioengineered heart valves signifies a groundbreaking milestone in cardiovascular medicine. Pioneering research illustrates how these advanced valves have revolutionized heart valve replacement procedures. By offering robust and biocompatible alternatives to conventional mechanical or tissue valves, bioengineered options represent a considerable leap forward in reducing complications and enhancing long-term patient outcomes including those by Malvindi, et al., (2020), highlight their remarkable similarity to native heart valves, thereby boosting their effectiveness and acceptance in clinical settings.

The in of bioengineered heart valves alongside minimally invasive surgical techniques has initiated a transformative shift in the management of heart valve diseases. Recent clinical trials, such as the CLASP IID/IIF trial, illustrate how this integration broadens the eligibility criteria for patients undergoing heart valve procedures. By lessening complications and expediting recovery, the collaboration between advanced surgical techniques and bioengineering not only optimizes patient outcomes but also ushers in an era of personalized medicine. This convergence enables the formulation of customized treatment strategies that promise to improve patient experiences and prognoses.

The interplay begineered heart valves and minimally invasive methods fosters the growth of precision medicine in the management of heart valve disorders. This innovative approach, as demonstrated by studies like the COAPT trial, underscores the importance of tailoring treatment plans to meet the individual needs of patients. By refining treatment strategies based on diverse factors such as age, lifestyle, and overall health, healthcare professionals can significantly enhance patient outcomes while minimizing potential risks. This transition toward precision medicine not only elevates the quality of patient care but also highlights the potential for ongoing advancements in the field.

The arrival of bioengineerlves, coupled with minimally invasive techniques, has considerably broadened the spectrum of treatment options available for heart valve disorders. Cutting-edge research illustrates how these valves provide durable and biocompatible alternatives to traditional prostheses. Furthermore, studies indicate that bioengineered valves closely mimic native tissue, paving the way for improved long-term outcomes. This expansion of treatment modalities empowers clinicians to tailor interventions to the specific needs of each patient, thereby optimizing care and enhancing the overall quality of life [39-43]. The collaborative progress in diagnosing and treating heart valve disorders, which includes bioengineered heart valves and minimally invasive techniques, epitomizes the ongoing evolution and innovation in cardiovascular medicine. These advancements, evidenced by landmark studies such as the CLASP IID/IIF and COAPT trials, promise continued enhancements in patient care and outcomes. As research and technology advance, the field of cardiovascular medicine is poised for further transformation, offering renewed hope and possibilities for patients globally.

Discussion

The global healthcare landscape faces mounting challenges, particularly with the rising incidence of cancer [43-52] and the persistent threat of infectious diseases [53-61], notably COVID-19. The pandemic has particularly strained healthcare systems worldwide, diverting critical resources and attention from other pressing health concerns. In this context, cardiovascular diseases (CVDs), particularly heart valve disorders, continue to pose significant and escalating challenges. Often overshadowed by more immediate health crises, heart valve disorders demand sustained focus due to their considerable morbidity and mortality rates. Recent advancements in diagnostic methodologies have substantially improved our capacity to detect and evaluate heart valve disorders. Echocardiography remains the cornerstone of diagnosis, providing real-time visualization of valve structures and functions. Transthoracic Echocardiography (TTE) and Transesophageal Echocardiography (TEE) offer invaluable imaging capabilities, with TEE providing superior resolution for complex cases.

Cardiac MRI and CT scans have emergel adjuncts to echocardiography, delivering enhanced soft tissue contrast and detailed anatomical visualization. Notably, cardiac MRI excels in assessing valve morphology and ventricular function without exposing patients to ionizing radiation. Meanwhile, cardiac CT offers precise imaging ofification and coronary anatomy, essential for procedural planning in transcatheter interventions. These advanced imaging modalities enable more accurate rication and treatment planning, ultimately contributing to improved patient outcomes.

Traditional surgical approaches, including open-heart surgery for valve repair or replacement, have long been regarded as the gold standard for treating severe valve disorders. However, these procedures are associated with considerable morbidity and prolonged recovery times. The advent of Minimally Invasive Surgical Techniques (MIST), such as Minimally Invasive Valve Surgery (MIVS) and Robotic-Assisted Valve Surgery, has transformed this field by minimizing operative trauma and enhancing recovery times. Transcatheter valve interventions, Including Transcatheter Aortic Cement (TAVR) and Transcatheter Mitral Valve Repair (TMVR), have further broadened treatment options. The PARTNER 3 trial demonstrated that TAVR is non-inferior to Surgical Aortic Valve Replacement (SAVR) in low-risk patients, accompanied by lower rates of stroke and mortality within the first year. Likewise, the COAPT trial highlighted the advantages of the MitraClip system howcasing significant reductions in heart failure hospitalizations and mortality compared to medical therapy alone.

Robotic-assisted valve surgery offers enhanced precision through the utilization of rocontrolled by surgeons. Research, including findings from Murphy, et al., (2021), reveals excellent procedural success rates and favorable short-term outcomes for mitral valve repairs utilizing robotic assistance. Moreover, the integration of Augmented Reality (AR) technologies into surgical procedures enhances visualization and navigation. Studies by Malvindi, et al., (2020) explore AR-assisted minimally invasive mitral valve repairs, demonstrating improved accuracy and reduced operative times. The development of bioengineered heart valves signifies a substantial advancement in valve repl innovative valves aim to closely replicate the structure and function of native tissues, offering enhanced biocompatibility and durability compared to traditional mechanical or bioprosthetic valves. Research underscores the potential of bioengineered valves to mitigate complications such as thrombosis and structural valve deterioration, ultimately leading to improved long-term patient outcomes [62-63].

Recent innovations, such as the Pascal system for edge-to-edge mitral valve repair, demonstrate promise in enhancing success rates and the durability of repairs. Bioengineered valves are particularly advantageous for younger patients, as they minimize the need for lifelong anticoagulationsociated with mechanical valves and reduce the risk of repeated interventions linked to bioprosthetic valves. The integration of advanced diagnostics, minimally invasive techniques, and bioengineered heart valves embodies the transition toward precision medicine in managing heart valve disorders. Personalized treatment strategies, tailored to the unique characteristics of individual patients-such as age, comorbidities, and anatomical variations-are becoming increasingly achievable. The synergy among these innovations facilitates more effective and less invasive treatment options, thereby enhancing patient experiences and outcomes. Studies like the CLASP IID/IIF trial emphasize the significance of individualized approaches, showcasing how the combination of bioengineered valves with minimally invasive techniques can broaden treatment eligibility and improve recovery. The COAPT trial further emphasizes the advantages of precision medicine, highlighting how specific patient populations can significantly m targeted therapies like the MitraClip system.

The advancements highlighted in this review are the product of collaborative efforts among clinicians, researchers, engineers, and other stakeholdisciplinary collaboration fosters innovation by merging expertise from various fields to tackle the complex challenges posed by heart valve disorders. This cooperation is crucial for translating research findings into clinical practice and for the ongoing development of novel technologies and treatment modalities.

Conclusion

The management of heart valve disorders has undergone a remarkable transformation, driven by innovations in diagnostic methodologies, minimally invasive surgical techniques, and the development of bioengineered heart valves. Collectively, these advancements significantly enhance patient care by reducing procedural risks and improving long-term outcomes. The integration of these cutting-edge technologies marks a paradigm shift toward precision medicine, allowing for personalized treatment approaches that address the unique needs of each patient. As research and technological advancements progress, the prospects for further enhancements in cardiovascular medicine remain substantial. Sustained interdisciplinary collaboration and a commitment to innovation will be vital in propelling these developments, ultimately leading to superior patient outcomes and an enhanced quality of life for individuals affected by heart valve disorders.

Acknowledgment

None.

Conflict of Interest

None.

References

• Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, et al. (2017) 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease. Journal of the American College of Cardiology 70(2): 252-289.
• Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, et al. (2007) Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. European Heart Journal 28(2): 230-268.
• Dweck MR, Boon NA, Newby DE (2012) Calcific aortic stenosis: A disease of the valve and the myocardium. Journal of the American College of Cardiology 60(19): 1854-1863.
• Ailawadi G, Szeto WY, Kern JA (2016) Minimally invasive aortic valve replacement: Progress continues. Journal of Thoracic and Cardiovascular Surgery 152(6): 1520-1522.
• Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, et al. (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. New England Journal of Medicine 364(23): 2187-2198.
• Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, et al. (2022) 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal 43(7): 561-632.
• Badylak SF, Weiss DJ, Caplan A, Macchiarini P (2012) Engineered whole organs and complex tissues. The Lancet 379(9819): 943-952.
• El Hamamsy, I, Yacoub MH (2009) Cellular and molecular mechanisms of thoracic aortic aneurysms. Nature Reviews Cardiology 6(12): 771-786.
• Yadlapati A, Windecker S (2019) Multimodality imaging for planning and guidance of transcatheter mitral valve therapies. JACC: Cardiovascular Imaging 12(6): 927-940.
• Ailawadi G, Szeto WY, Allen KB (2021) The Society of Thoracic Surgeons clinical practice guidelines on the management of aortic valve and ascending aorta conditions in adults. The Annals of Thoracic Surgery 111(1): 1-23.
• Seeburger J, Holzhey D, Borger MA, Schroeter T, Treede H, et al. (2020) Transcatheter mitral valve replacement: The next revolution in structural heart interventions? European Journal of Cardio-Thoracic Surgery 57(4): 732-740.
• Fioretta ES, Dijkman PE, Emmert MY (2021) The future of heart valve replacement: recent developments and translational challenges for heart valve tissue engineering. Journal of Tissue Engineering and Regenerative Medicine 15(2): 137-153.
• Chikwe J, Adams DH, Stuart JM (2021) Outcomes in minimally invasive versus sternotomy mitral valve surgery using national data. Journal of the American College of Cardiology 77(13): 1482-1490.
• Oveissi F, Naficy S, Lee A, Winlaw DS (2020) Materials and fabrication techniques for bioengineered heart valves. Advanced Materials 32(5): 1903713.
• Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, et al. (2021) 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology 77(4): 450-500.
• Otto CM, Prendergast B, Byrne JG, Chambers JB, Webb JG (2014) Aortic stenosis: Pathophysiology, diagnosis, and management. Lancet 383(9930): 822-833.
• Carapetis JR, Beaton A, Cunningham MW, Guilherme L, Karthikeyan G, et al. (2016) Acute rheumatic fever and rheumatic heart disease. Nature Reviews Disease Primers 2: 15084.
• Feldman T, Kar S, Elmariah S, Smart SC, Trento A, et al. (2015) Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. Journal of the American College of Cardiology 66(25): 2844-2854.
• Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, et al. (2017) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal 38(36): 2739-2791.
• Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin III JP, et al. (2020) 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135(25): e1159-e1195.
• Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, et al. (2014) Burden of tricuspid regurgitation in patients diagnosed in the catheterization laboratory setting. Journal of the American College of Cardiology 63(12): A1930.
• Iung B, Vahanian A, Denis B (2016) Prevalence of rheumatic heart disease worldwide and diagnosis of rheumatic fever: a current review. Heart 93(3): 235-239.
• Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler Jr VG, et al. (2009) Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Archives of Internal Medicine 169(5): 463-473.
• Zoghbi WA, Adams D, Bonow RO, Enriquez Sarano M, Foster E, et al. (2017) Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography. Journal of the American Society of Echocardiography 30(4): 303-371.
• Myerson SG, d'Arcy J, Mohiaddin R, Greenwood JP, Karamitsos TD, et al. (2018) Aortic regurgitation quantification using cardiovascular magnetic resonance: association with clinical outcome. Circulation 126(11): 1452-1460.
• Lee KB, Kim JB, Doh JH, Hwang JW, Kim YJ, et al. (2019) Quantitative assessment of aortic regurgitation using cardiac computed tomography: correlation with echocardiographic indices and impact of iterative reconstruction. Journal of Cardiovascular Computed Tomography 13(4): 225-231.
• Bonow RO, Brown AS, Gillam LD, Kapadia SR, Kavinsky CJ, et al. (2019) ACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/SCMR/STS 2017 appropriate use criteria for the treatment of patients with severe aortic stenosis: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Valve Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. Journal of the American College of Cardiology 70(23): 2566-2598.
• Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, et al. (2018) Biomarker monitoring in heart failure management: the role of natriuretic peptides. Journal of the American College of Cardiology 70(23): 2616-2631.
• Schmauss D, Haeberle S, Hagl C, Sodian R (2017) Three-dimensional printing in cardiac surgery and interventional cardiology: a single-centre experience. European Journal of Cardio-Thoracic Surgery 47(6): 1044-1052.
• Leon MB, Smith CR, Mack M, Miller DC, Moses JW, et al. (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. New England Journal of Medicine 374(17): 1609-1620.
• Arora R, Mukhopadhyay S, Palaniswamy C, Singh A, Gass A, et al. (2019) Balloon valvuloplasty in the modern era: technique, utility, and challenges. Heart Failure Clinics 15(2): 271-281.
• Holmes Jr DR, Kar S, Price MJ, Whisenant B (2015) Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. Journal of the American College of Cardiology 64(1): 1-12.
• David TE, Armstrong S, McCrindle BW, Manlhiot C (2013) Late outcomes of mitral valve repair for mitral regurgitation due to degenerative disease Circulation 140(Suppl1): A13392-A13392.
• Modi P, Chitwood Jr WR, Kron IL (2017) Minimally invasive mitral valve surgery: a systematic review and meta-analysis. European Journal of Cardio-Thoracic Surgery 51(5): 814-823.
• Murphy DA, Moss E, Binongo JN, Miller JS (2019) Robotic-assisted versus traditional cardiac surgery: a meta-analysis of perioperative outcomes and surgical quality indicators. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 14(4): 269-279.
• Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, et al. (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. New England Journal of Medicine 380(18): 1695-1705.
• Kapoor A, Goel PK, Gupta S, Tewari S, SinhaN, et al. (2018) Balloon mitral valvuloplasty in adults with pliable mitral stenosis: experience from a tertiary care centre in North India. Indian Heart Journal 70(3): 367-371.
• Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast BD, et al. (2018) Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. European Heart Journal 39(30): 2794-2806.
• Abdelaziz M, Roberts A (2020) Bioengineered heart valves: Current status and future perspectives. Frontiers in Cardiovascular Medicine 7: 608155.
• Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, et al. (2018) Transcatheter mitral-valve repair in patients with heart failure. New England Journal of Medicine 379(24): 2307-2318.
• Malvindi PG, Esposito M, Mastro F, Salsano A, Santini F, et al. (2020) Augmented reality for minimally invasive mitral valve surgery: a safe and useful tool for accurate navigation through complex anatomic structures. Journal of Cardiac Surgery 35(2): 311-314.
• Nickenig G, Weber M, Schueler R, Hausleiter J, Näbauer M, et al. (2021) Transcatheter mitral valve repair with the new Pascal device: early real-world data from a multi-center clinical experience. Journal of the American College of Cardiology 73(2): 252-261.
• Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, et al. (2022) Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA oncology 8(3): 420-444.
• Tran KB, Lang JJ, Compton K, Xu R, Acheson AR, et al. (2022) The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet 400(10352): 563-591.
• Sharma R, Abbasi Kangevari M, Abd Rabu R, Abidi H, Abu Gharbieh E, et al. (2022) Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Gastroenterology & Hepatology 7(7): 627-647.
• Alvarez EM, Force LM, Xu R, Compton K, Lu D, et al. (2022) The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Oncology 23(1): 27-52.
• Da Cunha AR, Compton K, Xu R, Mishra R, Drangsholt MT, et al. (2023) The global, regional, and national burden of adult lip, oral, and pharyngeal cancer in 204 countries and territories: A systematic analysis for the global burden of disease. JAMA Oncology 9(10): 1401-1416.
• Nejadghaderi SA, Moghaddam SS, Azadnajafabad S, Rezaei N, Seyed Mohammad T, et al. (2022) Burden of thyroid cancer in North Africa and Middle East 1990–2019. Frontiers in Oncology 12: 955358.
• Abbasi Kangevari M, Moghaddam SS, Ghamari SH, Azangou Khyavy M, Mohammad Reza M, et al. (2022) The burden of prostate cancer in North Africa and Middle East, 1990–2019: Findings from the global burden of disease study. Frontiers in Oncology 12: 961086.
• Azadnajafabad S, Moghaddam SS, Mohammadi E, Rezaei N, Mohammad Mahdi R, et al. (2023) Burden of breast cancer and attributable risk factors in the North Africa and Middle East region, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Frontiers in Oncology 13: 1132816.
• Piracha ZZ, Saeed U (2023) Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is downregulated in Invasive ductal carcinoma and potential prognostic marker of breast cancer. Journal of Cancer Research and Therapeutics 19(7): 1870-1879.
• Collaborative R, Zaborowski AM, Abdile A, Adamina M, Aigner F, et al. (2021) Characteristics of early-onset vs late-onset colorectal cancer: a review. JAMA surgery 156(9): 865-874.
• Ikuta KS, Swetschinski LR, Aguilar GR, Sharara F, Mestrovic T, et al. (2022) Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet 400(10369): 2221-2248.
• Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, et al. (2022) Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology & Hepatology 7(5): 396-415.
• Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi Kangevari M, et al. (2022) Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Gastroenterology & Hepatology 7(9): 796-829.
• Azhar A, Saeed U, Piracha ZZ, Amjad A, Ahmed A, et al. (2021) SARS-CoV-2 related HIV, HBV, RSV, VZV, Enteric viruses, Influenza, DENV, S. aureus and TB co-infections. Archives of Pathology and Clinical Research 5(1): 026-033.
• Piracha ZZ, Saeed U, Ahmed RAI, Khan FNA, Nasir MI, et al. (2023) Global emergence of Langya virus: A serious public health concern. Journal of Global Health 13: 03034.
• Piracha ZZ, Saeed U, Tariq MN, Gilani SS, Rauf M, et al. (2023) Emerging One Health Preparedness to Combat National Burden of Diseases in Pakistan: A Comprehensive Insight. Journal of Community Medicine and Health Solutions 4(2): 080-088.
• Piracha ZZ, Tariq MN, Rasool M, Gilani SS, Saeed U, et al. (2022) Catalyzing Global Action: Addressing SARS-CoV-2 Vaccine Hesitancy, Knowledge Disparities, and Epidemic Preparedness Challenges in Pakistan. Biomed J Sci & Tech Res 52(3): 43702-43707.
• Uppal SR, Uppal R, Khan AA, Saeed U, Piracha ZZ, et al. (2022) Estimating the Prevalence of Fungal Nail Infections and Potential Concerns for Central Disease Surveillance Hub in Pakistan. Archives of Clinical and Biomedical Research 6(3): 462-465.
• Uppal SR, Khan AA, Uppal R, Saeed U, Piracha ZZ, et al. (2022) Rising Surge of Antimicrobial Resistance and Urinary Tract Infections in Pakistani Children: A Potential Life-Threatening Scenario. Fortune Journal of Health Sciences 5(2): 281-283.
• Lurz J, Luecke C, Eitel C, Eitel I, Schuster A, et al. (2020) Cardiac Magnetic Resonance in Acute Myocarditis: Current Clinical Applications and Future Directions. Journal of the American College of Cardiology 75(5): 657-672.
• Piazza N, Tzikas A (2018) Access and closure for transcatheter aortic valve implantation (TAVI). EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 14(AB): AB8-AB14.